An oral formulation of Marinus Pharmaceuticals, Inc.’s ganaxolone has met its primary endpoint in the Phase III MARIGOLD study in patients with an rare, genetic form of severe epilepsy, markedly reducing the seizure frequency. The results are a boost for the GABA-A modulator, which has previously reported disappointing mid-stage clinical trial results in another indication, post-partum depression.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?